Development and characterization of liposomal formulations containing sesquiterpene lactones for the treatment of chronic gout

Development and characterization of liposomal formulations containing sesquiterpene lactones for the treatment of chronic gout

Gout and hyperuricemia are characterized by high uric acid levels, and their treatment involves medications that have adverse effects. In this study, we evaluated oral liposomal formulations with eremantholide C and goyazensolide as a novel approach to reduce the toxicity associated with these subst...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports Vol. 14; no. 1; p. 6991
Main Authors: Cunha Matosinhos, Rafaela, Frézard, Frédéric, Mendes Silva Araújo, Sabrina, Magalhães Barbosa, Andressa, de Souza, Isabela Fernanda, de Souza Filho, José Dias, de Souza, Jacqueline, Corrêa Oliveira Bahia, Ana Paula, Ietta, Francesca, Magnani, Agnese, Saúde-Guimarães, Dênia Antunes
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 24-03-2024
Nature Publishing Group
Nature Portfolio
Subjects:
631/45
631/45/607
639/925
639/925/352
639/925/352/152
692/4023
692/4023/1670
692/699/1670/3
692/699/1670/3/2765
Animals
Arthritis, Gouty
Bridged-Ring Compounds
Caco-2 Cells
Controlled release
Encapsulation
Furans
Gout
Gout - drug therapy
Humanities and Social Sciences
Humans
Hyperuricemia
Hyperuricemia - drug therapy
Lactones
Lactones - pharmacology
Lactones - therapeutic use
Liposomes
Liposomes - therapeutic use
multidisciplinary
Rats
Rheumatism
Science
Science (multidisciplinary)
Sesquiterpene lactones
Sesquiterpenes
Sesterterpenes
Size distribution
Toxicity
Uric acid
Uric Acid - therapeutic use
Zeta potential
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gout and hyperuricemia are characterized by high uric acid levels, and their treatment involves medications that have adverse effects. In this study, we evaluated oral liposomal formulations with eremantholide C and goyazensolide as a novel approach to reduce the toxicity associated with these substances while maintaining their anti-hyperuricemic activity. We characterized the formulations and evaluated them based on encapsulation efficiency and stability over 12 months and under simulated physiological environments. We determined the toxicity of the liposomal formulations in Caco-2 cells and the anti-hyperuricemic activity in rats. The formulations exhibited nanometric size, a narrow size distribution, and a negative zeta potential, indicating their stability and uniformity. The efficient encapsulation of the sesquiterpene lactones within the liposomes emphasizes their potential for sustained release and therapeutic efficacy. Stability evaluation revealed a small decrease in the eremantholide C concentration and a remarkable stability in the goyazensolide concentration. In Caco-2 cells, the liposomes did not exert toxicity, but did exhibit an antiproliferative effect. In vivo assays demonstrated that the liposomes reduced serum uric acid levels. Our study represents an advancement in gout and hyperuricemia treatment. The liposomal formulations effectively reduced the toxicity associated with the sesquiterpene lactones while maintaining their therapeutic effects.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-024-57663-1